Product Name: EBI3 Antibody
Species Reactivity: Human, Mouse
Tested Applications: ELISA, IF, IHC-P, WB
Applications: EBI3 antibody can be used for the detection of EBI3 by Western blot at 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: Predicted: 25 kDa
Immunogen: EBI3 antibody was raised against a 16 amino acid synthetic peptide from near the carboxy terminus of human EBI3.The immunogen is located within the last 50 amino acids of EBI3.
Host Species: Rabbit
Purification: EBI3 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 552325-16-3
Product: A-443654
Buffer: EBI3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: EBI3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: EBI3 Antibody: IL27B, IL-27B, IL27B, Interleukin-27 subunit beta, Epstein-Barr virus-induced gene 3 protein, IL-27 subunit beta
Accession NO.: NP_005746
Protein Ino: 14577917
Official Symbol: EBI3
Geneid: 10148
Background: EBI3 Antibody: EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35. Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naïve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.
PubMed ID:http://aac.asm.org/content/39/4/806.abstract
